ADG126 + Pembrolizumab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced Colorectal Cancer
Conditions
Locally Advanced Colorectal Cancer
Trial Timeline
Apr 14, 2025 → Dec 31, 2027
NCT ID
NCT06846268About ADG126 + Pembrolizumab
ADG126 + Pembrolizumab is a phase 2 stage product being developed by Adagene for Locally Advanced Colorectal Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06846268. Target conditions include Locally Advanced Colorectal Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06846268 | Phase 2 | Recruiting |
Competing Products
20 competing products in Locally Advanced Colorectal Cancer